Recombinant Full Length Human Tumor Necrosis Factor Ligand Superfamily Member 14(Tnfsf14) Protein, His-Tagged

Cat.No. : RFL23757HF
Product Overview : Recombinant Full Length Human Tumor necrosis factor ligand superfamily member 14(TNFSF14) Protein (O43557) (1-240aa), fused to N-terminal His tag, was expressed in E. coli.
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : E.coli expression system
Species : Homo sapiens (Human)
Tag : His
Form : Lyophilized powder
Protein length : Full Length (1-240)
AA Sequence : MEESVVRPSVFVVDGQTDIPFTRLG RSHRRQSCSVARVGLGLLLLLMGAG LAVQGWFLLQLHWRLGEMVTRLPDG PAGSWEQLIQERRSHEVNPAAHLTG ANSSLTGSGGPLLWETQLGLAFLRG LSYHDGALVVTKAGYYYIYSKVQLG GVGCPLGLASTITHGLYKRTPRYPE ELELLVSQQSPCGRATSSSRVWWDS SFLGGVVHLEAGEKVVVRVLDERLV RLRDGTRSYFGAFMV
Purity : Greater than 90% as determined by SDS-PAGE.
Applications : SDS-PAGE
Notes : Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Storage : Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Storage Buffer : Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution : We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Gene Name : TNFSF14
Synonyms : TNFSF14; HVEML; LIGHT; UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14; Herpes virus entry mediator ligand; HVEM-L; Herpesvirus entry mediator ligand; CD antigen CD258
UniProt ID : O43557
Gene Name : TNFSF14
Synonyms : TNFSF14; HVEML; LIGHT; UNQ391/PRO726; Tumor necrosis factor ligand superfamily member 14; Herpes virus entry mediator ligand; HVEM-L; Herpesvirus entry mediator ligand; CD antigen CD258
UniProt ID : O43557

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
07/28/2020

    The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

    08/01/2018

      It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

      06/19/2016

        The ability to obtain enduring results positively influenced the depth of our investigations.

        Q&As (7)

        Ask a question
        What are the primary changes induced by TNFSF14 in the tumor microenvironment? 05/19/2022

        TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

        What challenges remain in utilizing TNFSF14 for cancer immunotherapy? 07/02/2021

        While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

        What does TNFSF14 stand for? 02/05/2021

        TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

        How can TNFSF14 synergize with other immunotherapy modalities? 02/22/2020

        TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

        In what context has TNFSF14 been utilized to combat cancer? 02/06/2018

        TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

        How long has TNFSF14 been in pre-clinical development? 06/11/2017

        TNFSF14 has been in pre-clinical development for over a decade.

        What is the primary promise of TNFSF14 in the field of cancer immunotherapy? 08/15/2016

        TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.

        Ask a Question for All TNFSF14 Products

        Required fields are marked with *

        My Review for All TNFSF14 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends